IGF1R and thyroid cancer: However, the clinical translation of IGF-axis targeting in thyroid cancer remains limited, and IGF-1R-directed monotherapies have shown only modest efficacy owing to signaling redundancy, adaptive resistance, metabolic toxicities, and the lack of validated predictive biomarkers for patient selection.